Complement activation induces excessive T cell cytotoxicity in severe COVID-19

Georg, Philipp, Astaburuaga-García, Rosario, Bonaguro, Lorenzo, Brumhard, Sophia, Michalick, Laura, Lippert, Lena J., Kostevc, Tomislav, Gäbel, Christiane, Schneider, Maria, Streitz, Mathias, Demichev, Vadim, Gemünd, Ioanna, Barone, Matthias, Tober-Lau, Pinkus, Helbig, Elisa T., Hillus, David, Petrov, Lev, Stein, Julia, Dey, Hannah-Philine, Paclik, Daniela, Iwert, Christina, Mülleder, Michael, Aulakh, Simran Kaur, Djudjaj, Sonja, Bülow, Roman D., Mei, Henrik E., Schulz, Axel R., Thiel, Andreas, Hippenstiel, Stefan, Saliba, Antoine-Emmanuel, Eils, Roland, Lehmann, Irina, Mall, Marcus A., Stricker, Sebastian, Röhmel, Jobst, Corman, Victor M., Beule, Dieter, Wyler, Emanuel, Landthaler, Markus, Obermayer, Benedikt, von Stillfried, Saskia, Boor, Peter, Demir, Münevver, Wesselmann, Hans, Suttorp, Norbert, Uhrig, Alexander, Müller-Redetzky, Holger, Nattermann, Jacob, Kuebler, Wolfgang M., Meisel, Christian, Ralser, Markus, Schultze, Joachim L., Aschenbrenner, Anna C., Thibeault, Charlotte, Kurth, Florian, Sander, Leif E., Blüthgen, Nils, Sawitzki, Birgit·2022·Cell
DOI 10.1016/j.cell.2021.12.040

Cited by (222)

Items 201–222 of 222

  1. Von der Obduktion zur Translation
    Saskia Freifrau von Stillfried · 2025 · Die Pathologie
  2. Coronavirus disease 2019 and the SARS-CoV-2 variants: Virological perspectives
    Ankita Chakraborty, Bhabani Shankar Das, Sangita Lahiry, Debapriya Bhattacharya, Suprabhat Mukherjee · 2025 · Elsevier eBooks
  3. Additional file 3 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial
    Elisabeth De Leeuw, Karel F. A. Van Damme, Jozefien Declercq, Cédric Bosteels, Bastiaan Maes, Simon Jan Tavernier, Laurent Detalle, Trevor S Smart, Sophie Glatt, Nincy Debeuf et al. · 2022 · Figshare
  4. Additional file 1 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial
    Elisabeth De Leeuw, Karel F. A. Van Damme, Jozefien Declercq, Cédric Bosteels, Bastiaan Maes, Simon Jan Tavernier, Laurent Detalle, Trevor S Smart, Sophie Glatt, Nincy Debeuf et al. · 2022 · Figshare
  5. Additional file 2 of Integration of protein context improves protein-based COVID-19 patient stratification
    Gao, Jinlong, He, Jiale, Fangfei Zhang, Xiao, Qi, Cai, Xue, Yi, Xiao, Zheng, Siqi, Zhang, Ying, Wang, Donglian, Guangjun Zhu et al. · 2022 · Figshare
  6. Additional file 5 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial
    Elisabeth De Leeuw, Karel F. A. Van Damme, Jozefien Declercq, Cédric Bosteels, Bastiaan Maes, Simon Jan Tavernier, Laurent Detalle, Trevor S Smart, Sophie Glatt, Nincy Debeuf et al. · 2022 · Figshare
  7. Additional file 2 of Kinome and phosphoproteome reprogramming underlies the aberrant immune responses in critically ill COVID-19 patients
    Tomonori Kaneko, Sally Ezra, Rober Abdo, Courtney Voss, Shanshan Zhong, Xuguang liu, Hovey, Owen, Marat Slessarev, Logan R. Van Nynatten, Ye, Mingliang et al. · 2024 · Figshare
  8. Additional file 7 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial
    Elisabeth De Leeuw, Karel F. A. Van Damme, Jozefien Declercq, Cédric Bosteels, Bastiaan Maes, Simon Jan Tavernier, Laurent Detalle, Trevor S Smart, Sophie Glatt, Nincy Debeuf et al. · 2022 · Figshare
  9. Additional file 1 of Kinome and phosphoproteome reprogramming underlies the aberrant immune responses in critically ill COVID-19 patients
    Tomonori Kaneko, Sally Ezra, Rober Abdo, Courtney Voss, Shanshan Zhong, Xuguang liu, Hovey, Owen, Marat Slessarev, Logan R. Van Nynatten, Ye, Mingliang et al. · 2024 · Figshare
  10. Additional file 6 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial
    Elisabeth De Leeuw, Karel F. A. Van Damme, Jozefien Declercq, Cédric Bosteels, Bastiaan Maes, Simon Jan Tavernier, Laurent Detalle, Trevor S Smart, Sophie Glatt, Nincy Debeuf et al. · 2022 · Figshare
  11. Additional file 4 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial
    Elisabeth De Leeuw, Karel F. A. Van Damme, Jozefien Declercq, Cédric Bosteels, Bastiaan Maes, Simon Jan Tavernier, Laurent Detalle, Trevor S Smart, Sophie Glatt, Nincy Debeuf et al. · 2022 · Figshare
  12. Additional file 1 of Integration of protein context improves protein-based COVID-19 patient stratification
    Gao, Jinlong, He, Jiale, Fangfei Zhang, Xiao, Qi, Cai, Xue, Yi, Xiao, Zheng, Siqi, Zhang, Ying, Wang, Donglian, Guangjun Zhu et al. · 2022 · Figshare
  13. Additional file 2 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial
    Elisabeth De Leeuw, Karel F. A. Van Damme, Jozefien Declercq, Cédric Bosteels, Bastiaan Maes, Simon Jan Tavernier, Laurent Detalle, Trevor S Smart, Sophie Glatt, Nincy Debeuf et al. · 2022 · Figshare
  14. Single-cell atlas of COVID-19 based on multiple sample integration
    Pei Tang, Jinghan Wang, Hairui Li, Yong Qing, Zhixing Chen, Junliang Wu, Xiaolin Ran, Gang Zhong · 2025 · Medicine
  15. scTREND: An annotation-free single-cell time-resolved and condition-dependent hazard model
    Shintaro Yuki, Chikara Mizukoshi, Ko Abe, Teppei Shimamura · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  16. Widespread Molecular Imprints in the Serum Proteome of COVID-19 Convalescents Uncovering Immune System Sequelae
    Kun Liu, Zhigang Ren, Bowen Dong, Wenli Liu, Yuyuan Gao, Li Zhang, Jingyi Li, Zhao Sun, Hongyi Li, Qian Zhao et al. · 2026 · Molecular & Cellular Proteomics
  17. Mesenchymal stromal cell therapy for post-COVID-19 syndrome: associated impact and mechanism
    Yuefei Pan, Mengqi Yuan, Le Song, Weiqi Yao, Junli He, Qiong Mo, Ning Zheng, Ziying Zhang, Tengyun Dong, Kaidi Zhu et al. · 2026 · Journal of Translational Medicine
  18. A Comprehensive Assessment of Post-COVID-19 Changes and Its Correction with the Help of G. Lucidum and Alkhaday
    Abilov Mеlisovich · 2026 · American Journal of Medical Science and Technology
  19. Integrated proteomic and metabolomic profiling characterizes tryptophan metabolic disturbance associated with mortality in ICU-admitted SFTS patients
    Li Chen, Puhui LIU, Chuanzhen Niu, Chenxiao Hao, Fengxue Zhu, Guangjie Wang, H. Zhao · 2026 · Frontiers in Immunology
  20. Antioxidant, Anti-infective and Anticoagulant Properties of Ganoderma Lucidum and Alkhadaya in the Comprehensive Correction of Coronavirus Infection COVID-19
    N. T. Nurmatova · 2026
  21. Complement C3a plays a role in diabetic cardiomyopathy mainly via C3aR-ERK-PANoptosis pathway
    Yueqi Zhang, Yang Xie, Lingyun Wang, Xiaodan Zhong, Mengwen Wang, Lingyun Luo, Ping Lei, Ping Lai, Lina Li, Alexandra Váczy et al. · 2026 · International Immunopharmacology
  22. BindingDB Entry 50022764: Discovery of Chalcone Derivatives as Bifunctional Molecules with Anti-SARS-CoV-2 and Anti-inflammatory Activities.
    BindingDB · 2026 · UC San Diego